Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood–brain-barrier
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (2) , 453-457
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitationPharmacological Research, 2009
- The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulationInternational Journal of Obesity, 2009
- The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity AgentsCurrent Topics in Medicinal Chemistry, 2009
- Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosisExpert Opinion on Emerging Drugs, 2009
- An introduction to the endocannabinoid system: from the early to the latest conceptsBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- A critical review of the cannabinoid receptor as a drug target for obesity managementObesity Reviews, 2008
- CB1 receptor antagonism: biological basis for metabolic effectsDrug Discovery Today, 2008
- The endocannabinoid system in obesity and type 2 diabetesDiabetologia, 2008
- Cannabinoid Receptors: Where They are and What They doJournal of Neuroendocrinology, 2008
- CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivityInternational Journal of Obesity, 2004